(Barcelona, Spain, Thursday, 25 September 2025) New research presented today at the 41 st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals ...
The leading research and educational conference for multiple sclerosis healthcare professionals in North America, the Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting, returns to ...
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas ...
Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. TG Therapeutics, Inc. announced the schedule for presentations on data ...
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...
Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results